Overview

An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in stage III-IV chronic kidney disease patients not on dialysis receiving Mircera for the treatment of chronic renal anemia. Eligible patients will be followed for 24 weeks.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Epoetin Alfa